European Psychiatry - Volume 33 - March 2016

121 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S117
EW03
Predictors for readmission within one
year after discharge from an alcohol
rehabilitation program
M. Müller∗, G. Weniger , S. Prinz , S. Vetter , S. Egger
University Hospital for Psychiatry Zurich, ZIP-Rheinau, Zurich,
Switzerland
∗ Corresponding author.
Introduction Alcohol use disorders have been associated with an
increased risk of frequent readmissions. This study aimed to exam-
ine factors that contribute to the risk for readmission within one
year after discharge from an alcohol rehabilitation program.
Methods Rehospitalization status was assessed for all patients
with an alcohol use disorder as primary diagnosis (n = 468) admit-
ted to our inpatient unit between July 1, 2012, and June 30, 2014.
All patients were followed up for one year after their first hos-
pitalization (index hospitalization) within this period. Time to
readmission within one year after discharge was measured using
the Kaplan–Meiermethod. Risk factors for readmissionwere exam-
ined using Cox proportional hazard regression models. Three set of
variables were selected to be included in the analyses:
– demographic features at time of admission of index hospitaliza-
tion;
– comorbid conditions at time of admission of index hospitaliza-
tion;
– treatment-related variables in relation to the index hospitaliza-
tion including observer-rated outcome measures.
Results Readmissions within one year after discharge from an
alcohol rehabilitation program as well as the corresponding time
to readmission were linked to higher numbers of previous hospi-
talizations and the presence of comorbid opioid use disorders.
Conclusion Higher numbers of past treatments for AUD are indi-
cators for a chronic course of the disorder, which, in turn, increase
the risk of further relapses. Our findings further confirmed previous
findings suggesting high rates of comorbidity among alcohol and
opioid use disorders, and their link with poorer clinical outcomes.
Keywords Alcohol use disorder; Alcohol rehabilitation
program; Readmission; Survival analysis
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW04
Interactions between mephedrone
and alcohol in humans:
Cardiovascular and subjective effects
M. Farré ∗, C. Perez-Ma˜na , E. de Souza , J. Mateus ,
E. Theunisen , K. Kuypers , J. Ramaekers , F. Fonseca ,
M. Torrens , E. Olesti , R. de la Torre , E. Papaseit
1 Hospital Universitari Germans Trias i Pujol-IGTP-IMIM-UAB,
Clinical Phamacology, Badalona, Spain
2 Hospital del Mar Medical Research Institute-IMIM-UAB and UPF,
Human Pharmacology, Badalona, Spain
3 Faculty of Psychology and Neuroscience, Maastricht University,
Neuropsychology and Psychopharmacology, Maastricht, Netherlands
4 Institut de Neuropsiquiatria i Addiccions, Parc de Salut
Mar-IMIM-UAB, Addiction Unit, Badalona, Spain
∗ Corresponding author.
Introduction Mephedrone is a synthetic cathinone deriva-
tive included in the class of “New-Novel Psychoactive Sub-
stances”. Synthetic cathinones are marketed as “bath salts” or
“plant food” and gained notable popularity for similar effects
to 4-methylenedioxymethamphetamine (MDMA, ecstasy), or
amphetamines. Mephedrone is commonly consumed simulta-
neously with alcohol.
Objectives and aims The aim of the present study was to evaluate
the interactions between mephedrone and ethanol in humans.
Methods Twelve healthy male, recreational users of psychostim-
ulants participated as outpatients in four experimental sessions.
They received a single oral dose of mephedrone (200mg) and
alcohol (0.8 g/kg), mephedrone placebo and alcohol (0.8 g/kg),
mephedrone (200mg) and placebo alcohol, and both placebos.
Design was double-blind, double-dummy, randomized, cross-over
and controlled with placebo. Study variables included: vital signs
(blood pressure, heart rate, temperature, and pupil diameter), sub-
jective effects (visual analogue scales-VAS, ARCI-49 item short
form, and VESSPA questionnaire).
Results The combination produced an increase in the cardiovas-
cular effects of mephedrone and induced more intense feeling of
euphoria and well-being in comparison to mephedrone and alco-
hol. Mephedrone reduced the drunkenness and sedation produced
by alcohol.
Conclusions These results are similar to those obtained with
the combination of other psychostimulants as amphetamines and
MDMA. Abuse liability of the combination is greater that induced
by mephedrone.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Acknowledgements Supported by grants from Instituto de Salud
Carlos III (ISCIII, FIS-FEDER, FIS PI11/01961), ISCIII-Red de
Trastornos Adictivos (RTA RD12/0028/0009), and The European
Commission (JUST/2013/DPIP/AG/4823, EU-MADNESS project).
Clara Pérez-Ma˜ná and Esther Papaseit are Rio Hortega-Juan Rodes
fellowship (ISCIII, CM12/00085, CM13/00016, JR15/00005).
EW05
The synthetic cannabinoids: JWH, four
years of analysis
L. Galindo ∗, M. Grifell , P. Quintana , A. Palma , J. Tirado ,
M. Ventura , I. Fornis , M. Torrens , M. Farré
1 Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, IMIM,
Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain
2 Energy Control, Asociación Bienestar y Desarrollo, Energy Control,
Parc de Salut Mar, Medina de Familia, Barcelona, Spain
3 IMIM, Adictions, Barcelona, Spain
4 Energy Control, Asociación Bienestar y Desarrollo, Energy Control,
Barcelona, Spain
5 Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, IMIM,
Universitat Autònoma de Barcelona-, Adictions, Barcelona, Spain
6 Hospital Universitari Germans Trías i Pujol, IGTP, Universitat
Autònoma de Barcelona, Pharmacology, Barcelona, Spain
∗ Corresponding author.
Introduction Since 2004, herbal mixtures for smoking use have
been sold under the generic brand “Spice”. Many of them contain
synthetic cannabinoids (agonists of the cannabinoid receptors).
JWH-018 was one of the first spice drugs. There is no scientific evi-
dence of their effects on humans, except cases of intoxications and
users opinions.
Objective The present study describes the presence of the syn-
thetic cannabinoids JWH’s and their characteristics in the samples
delivered for analysis to the harm reduction NGO Energy Control
from 2010 to 2014 in Spain.
Methods From15,814 samples analyzed from2010 to 2014, those
containing synthetic cannabinoids JWH’s were studied (n = 47).
Analysis was done by gas chromatography–mass spectrometry.
Results From these 47 samples containing JWH, 55% were deliv-
ered as “legal highs” (n = 21) and 44% as JWH. Most common
presentations were powder 47% and herbals 32%. Samples con-
taining JWH 45%(n = 21) were mixed with more than one kind of
JWH or were adulterated and other active principles were found
28% (n = 13) JWH-018, 11% (n = 5) JWH-210, 8% (n = 4) JWH-081 and